MedTrace Logo

Phase I Study of Indibulin in Patients With Solid Tumors

NCT00591136 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2012-07-19

No results posted yet for this study

Summary

Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.

Conditions

Interventions

DRUG

indibulin

Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jonathan Lewis, MD, PhD · ZIOPHARM Oncology, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591136 on ClinicalTrials.gov